fashion -WSS

fashion

author：hotspot 2025-10-01 20:16:32 - browse：89

A photo of Robert Blum speaking at the STAT Summit West on May 16, 2024 — Cytokinetics CEO Robert Blum spoke last week at a talk during STAT’s Breakthrough Summit West in San Francisco. Sarah Gonzalez for STAT

Cytokinetics, a drugmaker that is expected to soon launch a promising new heart therapy called aficamten, said Wednesday that it had agreed to pay biotech firm Royalty Pharma a higher royalty on the medicine in return for up to $575 million, which will be used to fund the marketing of the drug and Cytokinetics’ ongoing research and development efforts.

Cytokinetics shares fell nearly 10% in after-hours trading after the announcement, which investors viewed as lowering the odds that the company will be purchased by a larger pharmaceutical company.

The firm also said that it would be raising $500 million through a stock sale.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： New weight loss drugs work. But how can they best be used?

WSS

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

Resistance to cancer drugs: A new genetic explanation

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

U.K. sequencing study surfaces new findings about tumor DNA

The kidney, in all its complexity, is captured in a new atlas

U.K. sequencing study surfaces new findings about tumor DNA

knowledge

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Medicare details structure of new drug price negotiation program

Goldman Sachs launches $650M fund for life science investments

Supreme Court strikes down use of affirmative action

Norman Reedus' Daryl Dixon

Sports medicine is finally prioritizing gender equality

New weight loss drugs work. But how can they best be used?

Medicare details structure of new drug price negotiation program

New weight loss drugs work. But how can they best be used?

Malaria cases in Florida and Texas: Here’s what you need to know

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

focus

3 medical device trends to watch in 2024

No Labels group has 'steep climb,' but third party 'worth trying': Larry Hogan

States increasingly look to regulate hospital facility fees

3 trends to watch in health tech's hiring outlook for 2024

Suspected Gilgo Beach killer appeared 'traumatized' after arrest: Defense attorney

Seattle police shoot person suspected in downtown stabbing

hotspot

hotspot

entertainment

Wikipedia